ZBIO - Zenas BioPharma • Financials

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year	Revenue	EBITDA	Net Inc	Net Mrg	EPS	Equity	ROE	Net Debt Aj	ND/EBITDA Aj	OCF Aj	Capex	FCF	Free Aj	Buyback	Dividend	Payout	DY
12/2022	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2023	50	-37	-	L	L	-226	L	-37	-	-34	-0	20	-34	0	0	-	-
12/2024	5	-164	-	L	L	312	L	-351	-	-130	-0	413	-131	0	0	-	-
12/2025	10	-383	-	L	L	242	L	-343	-	-199	-0	215	-199	0	0	-	-

To see all financials—including updated, you must be Premium.